Funder: Breakthrough T1D

Due Dates: December 5, 2024 (Webinar) | January 10, 2025 (Letter of Intent) | February 21, 2025 (Full Proposal)

Funding Amounts: Up to $300,000/year for 2 years (total up to $600,000); larger awards possible with prior approval.

Summary: Supports research advancing technologies to improve survival, engraftment, and function of insulin-producing cells at extrahepatic sites for T1D cell therapy.

Key Information: Preclinical and early clinical-stage projects prioritized; both academic and industry applicants eligible.